CTLA4 and metastatic melanoma: Ipilimumab is a monoclonal antibody that inhibits CTLA-4, permitting rapid expansion of T cells primed by antigen presenting cells (1) and was the first treatment to show a survival benefit in metastatic melanoma (2).